{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T20:22:51Z","timestamp":1794082971042,"version":"4.8.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41433-026-04713-9","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:47:13Z","timestamp":1783619233000},"page":"2228-2234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of intravitreal anti-VEGF treatment burden in different retinal diseases"],"prefix":"10.1038","volume":"40","author":[{"given":"Raffael","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1124-6531","authenticated-orcid":false,"given":"Lisa-Maria","family":"Weissenbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"V\u00e9csei-Marlovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1110-0432","authenticated-orcid":false,"given":"Birgit","family":"Weingessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"4713_CR1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1001\/jamaophthalmol.2021.5619","volume":"140","author":"S Gurudas","year":"2022","unstructured":"Gurudas S, Patrao N, Nicholson L, Sen P, Ramu J, Sivaprasad S, et al. Visual outcomes associated with patterns of macular edema resolution in central retinal vein occlusion treated with anti\u2013vascular endothelial growth factor therapy. JAMA Ophthalmol. 2022;140:143 https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2787670.","journal-title":"JAMA Ophthalmol"},{"key":"4713_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/2042018813512360","volume":"4","author":"DS Boyer","year":"2013","unstructured":"Boyer DS, Hopkins JJ, Sorof J, Ehrlich JS. Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab. 2013;4:151\u201369.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"4713_CR3","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ophtha.2015.09.035","volume":"123","author":"WL Clark","year":"2016","unstructured":"Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion. Ophthalmology. 2016;123:330\u20136. https:\/\/doi.org\/10.1016\/j.ophtha.2015.09.035.","journal-title":"Ophthalmology"},{"key":"4713_CR4","doi-asserted-by":"crossref","unstructured":"Wykoff CC, Clark; WL, Nielsen JS, Brill JV, Greene LS, Heggen CL. Journal of Managed Care & speCialty pharMaCy Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration.; 2018. Available at: www.jmcp.orgwww.amcp.org.","DOI":"10.18553\/jmcp.2018.24.2-a.s3"},{"key":"4713_CR5","doi-asserted-by":"publisher","unstructured":"Debourdeau E, Beylerian H, Nguyen V, Barthelmes D, Gillies M, Gabrielle PH, et al. Treat-and-extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study from routine clinical practice. Ophthalmol Ther. 2024;13:2343\u201355. https:\/\/doi.org\/10.1007\/s40123-024-00983-2.","DOI":"10.1007\/s40123-024-00983-2"},{"key":"4713_CR6","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00347-020-01273-5","volume":"118","author":"A Lommatzsch","year":"2021","unstructured":"Lommatzsch A, Eter N, Ehlken C, Lanzl I, Kaymak H, Schuster AK, et al. Adherence to anti-VEGF treatment\u2014Considerations and practical recommendations. Ophthalmologe. 2021;118:801\u20139.","journal-title":"Ophthalmologe"},{"key":"4713_CR7","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1111\/aos.15201","volume":"101","author":"RP Gale","year":"2023","unstructured":"Gale RP, Finger RP, Eldem B, Aslam T, Barratt J, Daien V, et al. The management of neovascular age-related macular degeneration: A systematic literature review of patient-reported outcomes, patient mental health and caregiver burden. Acta Ophthalmol. 2023;101:e26\u2013e42.","journal-title":"Acta Ophthalmol"},{"key":"4713_CR8","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/aos.15783","volume":"102","author":"E Vinge","year":"2024","unstructured":"Vinge E, Bro T. Treatment burden on patients receiving intravitreal anti-VEGF for wet age-related macular degeneration. Acta Ophthalmol. 2024;102:478\u201382.","journal-title":"Acta Ophthalmol"},{"key":"4713_CR9","doi-asserted-by":"publisher","unstructured":"Demain S, Gon\u00e7alves AC, Areia C, Oliveira R, Marcos AJ, Marques A, et al. Living with, managing and minimising treatment burden in long term conditions: a systematic review of qualitative research. PLoS One. 2015;10:e0125457. https:\/\/doi.org\/10.1371\/journal.pone.0125457.","DOI":"10.1371\/journal.pone.0125457"},{"key":"4713_CR10","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ajo.2015.06.023","volume":"160","author":"JL Prenner","year":"2015","unstructured":"Prenner JL, Halperin LS, Rycroft C, Hogue S, Williams Liu Z, Seibert R. Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. Am J Ophthalmol. 2015;160:725\u2013731.e1.","journal-title":"Am J Ophthalmol"},{"key":"4713_CR11","first-page":"311","volume":"67","author":"N Holekamp","year":"2024","unstructured":"Holekamp N, Gentile B, Giocanti-Aur\u00e9gan A, Garc\u00eda-Layana A, Peto T, Viola F, et al. Patient experience survey of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration and diabetic macular edema. Ophthalmic Res. 2024;67:311\u201321.","journal-title":"Ophthalmic Res"},{"key":"4713_CR12","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00347-019-01005-4","volume":"117","author":"FG Holz","year":"2020","unstructured":"Holz FG, Johnson KT, Bauer-Steinhusen U, Rech C, Machewitz T, M\u00fcller S, et al. ANDROMEDA\u2014an investigation of factors influencing the adherence of patients with neovascular age-related macular degeneration using the newly developed patient questionnaire LAF-IVT. Ophthalmologe. 2020;117:765\u201374.","journal-title":"Ophthalmologe"},{"key":"4713_CR13","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jfo.2014.11.015","volume":"38","author":"E Boulanger-Scemama","year":"2015","unstructured":"Boulanger-Scemama E, Querques G, About F, Puche N, Srour M, Mane V, et al. Ranibizumab for exudative age-related macular degeneration: A five year study of adherence to follow-up in a real-life setting. J Fr Ophtalmol. 2015;38:620\u20137.","journal-title":"J Fr Ophtalmol"},{"key":"4713_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/13548506.2016.1274040","volume":"23","author":"J Boyle","year":"2014","unstructured":"Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C, Rees G. Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Health Med. 2014;23:127\u201340.","journal-title":"Psychol Health Med"},{"key":"4713_CR15","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1007\/s00417-017-3739-1","volume":"255","author":"S M\u00fcller","year":"2017","unstructured":"M\u00fcller S, Ehlken C, Bauer-Steinhusen U, Lechtenfeld W, Hasanbasic Z, Agostini H, et al. Treatment of age-related neovascular macular degeneration: the patient\u2019s perspective. Graefe\u2019s Arch Clin Exp Ophthalmol. 2017;255:2237\u201346.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"4713_CR16","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00417-020-04798-2","volume":"258","author":"C Ehlken","year":"2020","unstructured":"Ehlken C, Ziemssen F, Eter N, Lanzl I, Kaymak H, Lommatzsch A, et al. Systematic review: non-adherence and non-persistence in intravitreal treatment. Graefe\u2019s Arch Clin Exp Ophthalmol. 2020;258:2077\u201390.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04713-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04713-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04713-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:45:38Z","timestamp":1790167538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04713-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":16,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["4713"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04713-9","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}